Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline in Hepatopulmonary Syndrome
NCT05373134Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of pentoxifylline in hepatopulmonary syndrome (HPS), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Alveolar-arterial oxygen gradient at 6 months. Status: unknown.
02
Drugs
pentoxifylline
03
Conditions
hepatopulmonary syndrome (HPS)
Beyond the preview
Go deeper on NCT05373134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373134.